Brokerages forecast that Xenon Pharmaceuticals Inc (NASDAQ:XENE) will post $6.38 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Xenon Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $250,000.00 and the highest estimate coming in at $12.50 million. Xenon Pharmaceuticals posted sales of $380,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 1,578.9%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 14th.
According to Zacks, analysts expect that Xenon Pharmaceuticals will report full year sales of $6.38 million for the current financial year, with estimates ranging from $550,000.00 to $12.80 million. For the next fiscal year, analysts anticipate that the company will report sales of $7.75 million per share, with estimates ranging from $2.00 million to $13.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Xenon Pharmaceuticals.
Separately, Zacks Investment Research upgraded Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, October 5th.
In related news, Director Mohammad Azab acquired 15,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were acquired at an average price of $2.22 per share, for a total transaction of $33,300.00. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 9.40% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in the business. DAFNA Capital Management LLC boosted its position in Xenon Pharmaceuticals by 11.2% in the 2nd quarter. DAFNA Capital Management LLC now owns 377,695 shares of the biopharmaceutical company’s stock worth $1,190,000 after purchasing an additional 38,081 shares in the last quarter. K2 Principal Fund L.P. raised its stake in shares of Xenon Pharmaceuticals by 40.6% during the 2nd quarter. K2 Principal Fund L.P. now owns 164,510 shares of the biopharmaceutical company’s stock worth $518,000 after buying an additional 47,535 shares during the period. Finally, Scotia Capital Inc. raised its stake in shares of Xenon Pharmaceuticals by 36.0% during the 2nd quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 9,426 shares during the period. Institutional investors and hedge funds own 54.62% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “$6.38 Million in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter” was originally reported by BBNS and is owned by of BBNS. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://baseballnewssource.com/markets/6-38-million-in-sales-expected-for-xenon-pharmaceuticals-inc-xene-this-quarter/1798843.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with our FREE daily email newsletter.